Semax
9 articles on Semax, researched and written by the Shotlee Editorial Team from primary sources.
What's the Deal with Peptides? The Hyped Market Under FDA Review
An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.
8 min read
New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It
New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.
8 min read
Peptides Get Their Regulatory Close-Up at FDA Review
The FDA is convening a panel to review regulations on popular injectable peptides. Learn about safety concerns, clinical evidence gaps, and what this means for patient access to peptide therapy.
8 min read
Peptide Use Among Young Men: The Pursuit of Perfection and Potential Risks
The quest for physical perfection is driving a new trend among teen boys and young men: the use of unapproved peptides. This article delves into the motivations, the substances involved, and the significant health concerns surrounding this practice.
8 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
Beware the Peptide Übermensch: Biohacking's New Frontier
In Manhattan medspas and Bushwick fridges, peptides are fueling a quest for the perfect body—from GLP-1 pens vanquishing appetite to experimental vials promising telomere extension. But as biohackers chase the peptide Übermensch, what hidden costs lurk in this shift from treating illness to perfecting the self? Discover the cultural frenzy, market divides, and societal stakes.
4 min read
Semax: Potential of a Synthetic Peptide in Neuroscience Research
Semax, a synthetic heptapeptide derived from ACTH research, is capturing interest for its neuroactive properties without endocrine effects. Ongoing studies highlight its roles in neuroplasticity, stress resilience, and cognitive function. This guide delves into the science behind its multifaceted research potential.
5 min read
Semax Peptide: Research on Neuroprotection, Inflammation, and Vascular Effects
Semax, a synthetic heptapeptide, has demonstrated neuroregulatory, neuroprotective, and immunomodulating properties in various research models. This article examines its biochemical characteristics, possible effects on gene expression, interactions with neurotransmitter systems, vascular modulation, metal binding, and utility in ischemia-reperfusion injury studies.
5 min read